Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 765423 in Idiopathic Pulmonary Fibrosis
NCT07036523Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2025
- Primary completion
- Mar 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing BI 765423 with Placebo (2 arms). Primary endpoint: Forced Vital Capacity at 12 weeks. Started Nov 2025; status: active, not recruiting.
02
Drugs
BI-765423
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07036523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07036523.